BMB-105

BMB-105
Clinical data
Other namesBMB105
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT2C receptor agonist
ATC code
  • None

BMB-105 is a selective serotonin 5-HT2C receptor agonist of the phenylcyclopropylmethylamine (PCPMA) family which is under development for the treatment of excessive appetite and other symptoms in Prader–Willi syndrome.[1][2][3][4] It is taken orally.[1]

The drug is described as a highly selective biased agonist of the serotonin 5-HT2C receptor, with activation of the Gq signaling pathway but minimal β-arrestin recruitment.[4]

BMB-105 is under development by Bright Minds Biosciences.[1][2][3][4] As of November 2025, it is in phase 1 clinical trials.[1][3] The drug is described as a follow-on drug to Bright Mind Bioscience's more advanced candidate BMB-101 and as a potential "best-in-class" medication.[3][4]

The exact chemical structure of BMB-105 does not yet appear to have been disclosed.[1] However, it is known to be a 2-phenylcyclopropylmethylamine (PCPMA) derivative similarly to BMB-101 and to share structural commonalities with tranylcypromine.[4]

See also

References

  1. ^ a b c d e f "BMB 105". AdisInsight. 28 January 2026. Retrieved 27 March 2026.
  2. ^ a b "Delving into the Latest Updates on BMB-105 with Synapse". Synapse. 24 January 2026. Retrieved 27 March 2026.
  3. ^ a b c d Bryson S (13 November 2025). "Can BMB-105 ease insatiable hunger in PWS? Program to find out". Prader-Willi Syndrome News. Retrieved 27 March 2026.
  4. ^ a b c d e Vasilkevich A, Lovera A, Duan J, McDonald I, Collins SD, Pedersen JT (7 December 2025). Overview of Bright Minds Biosciences: Pioneering Serotonin Pharmacology (PDF). 2025 AES Annual Meeting, December 5–9, Atlanta, Georgia.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.